Corxel Pharmaceuticals, a clinical-stage biopharmaceutical company specializing in metabolic and cardiovascular medicines, has entered into a definitive business combination agreement with Amanat Acquisition Corp. (Nasdaq: AMAN), a special purpose acquisition company (SPAC). The transaction is structured to provide Corxel with approximately $377 million in gross proceeds, positioning the company to advance its lead candidate, an oral small-molecule GLP-1 receptor agonist, into pivotal Phase 3 clinical trials. The merger, announced on Monday, represents a significant move in the rapidly evolving obesity therapeutics sector, where the demand for convenient, scalable, and tolerable oral alternatives to injectable treatments continues to surge.
Under the terms of the agreement, the combined entity will operate under a new corporate name and trade under a new ticker symbol, both of which will be disclosed prior to the transaction’s closing. The deal is expected to finalize in the first half of 2027, subject to shareholder approval and customary closing conditions. The influx of capital is projected to extend Corxel’s operational runway into 2029, providing the financial stability necessary to navigate the rigorous late-stage regulatory and clinical landscape.
The Strategic Focus on Oral GLP-1 Therapeutics
Corxel’s primary value driver is CX11, a once-daily, oral small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist. While the obesity market is currently dominated by injectable peptides such as Novo Nordisk’s Wegovy (semaglutide) and Eli Lilly’s Zepbound (tirzepatide), the industry is shifting toward oral formulations. Small molecules like CX11 offer distinct advantages over peptides, including easier manufacturing scalability and the elimination of "cold-chain" storage requirements, which are essential for global distribution.
In preliminary results from a Phase 2 clinical trial involving U.S. adults with obesity or who are overweight, CX11 demonstrated a mean weight loss of up to 11.5% at the 36-week mark. While cross-trial comparisons are subject to variations in study design and patient populations, Corxel’s data suggests that CX11 is competitive with the mid-stage results of other oral GLP-1 candidates, including Novo Nordisk’s oral high-dose semaglutide and Eli Lilly’s orforglipron.
A critical differentiator for CX11 lies in its tolerability profile. Gastrointestinal (GI) side effects, such as nausea and vomiting, are the most frequent reasons for patient discontinuation of GLP-1 therapies. Corxel reported a vomiting rate between 12% and 16% in its Phase 2 study, which the company characterized as "markedly lower" than the rates observed in similar trials for competing oral drugs. The discontinuation rate for CX11 was approximately 5%, and the company reported no signals of liver toxicity—a common concern for small-molecule metabolic drugs.
Chronology of Development and Corporate Evolution
The path to this public listing began in 2019 when RTW Investments, a prominent life sciences investment firm, founded Corxel Group. Initially known as JiXing Pharmaceuticals in China, the group was designed to bridge the gap between global innovation and the Chinese market, while simultaneously developing a proprietary pipeline for international markets.
In 2024, Corxel strategically expanded its portfolio by acquiring the molecule that became CX11 from Vincentage Pharma. This acquisition pivoted the company’s focus toward the lucrative obesity and type 2 diabetes markets. Since then, the company has accelerated its clinical programs, completing Phase 3 testing for CX11 in Asia and successfully executing the Phase 2 U.S. trial.
The timeline for the upcoming year is dense with milestones:
- First Half of 2025: Expected release of preliminary data from a mid-stage study evaluating CX11 in patients with type 2 diabetes mellitus.
- Late 2026/Early 2027: Anticipated close of the business combination with Amanat Acquisition Corp.
- First Half of 2027: Commencement of the Phase 3 clinical program for CX11 in obesity, following a design already agreed upon with the U.S. Food and Drug Administration (FDA).
- First Half of 2027: Planned filing of an Investigational New Drug (IND) application for CX12, an internally developed oral small molecule targeting the amylin receptor.
Financial Architecture and PIPE Financing
The $377 million in gross proceeds is comprised of two primary components. First, the transaction includes approximately $75 million currently held in Amanat Acquisition Corp.’s trust account, assuming no significant redemptions by the SPAC’s existing shareholders. Second, the deal is bolstered by a $300 million private placement in public equity (PIPE) financing.
The PIPE round has attracted a sophisticated syndicate of institutional healthcare and biotech investors. Participants include RTW Investments, New Enterprise Associates (NEA), SR One, Mirae Asset Capital Life Science, and HBM Healthcare Investments. Other notable investors include Nantahala Capital, Coastlands Capital, LifeSci Venture Partners, Invus, TCGX, RA Capital Management, and Propel Bio. A large, unnamed healthcare mutual fund also committed to the round.
Upon completion of the merger, the PIPE investors are expected to hold a 50.1% majority stake in the combined company. Corxel Group, the parent organization, will retain a 33.4% ownership interest, while Amanat’s public shareholders will own approximately 12.8%, provided they do not opt for share redemption. This ownership structure reflects strong institutional confidence in Corxel’s clinical data and its ability to compete in the high-stakes metabolic space.
Market Context and Competitive Landscape
The global market for obesity medications is projected to reach $100 billion by the early 2030s. This immense financial opportunity has sparked a "gold rush" among pharmaceutical companies. Corxel enters a field that is becoming increasingly crowded, as major players and well-funded biotechs race to bring the first highly effective "weight-loss pill" to market.
In addition to the established leaders, Novo Nordisk and Eli Lilly, several other firms are advancing oral GLP-1 candidates:
- AstraZeneca: Currently developing ECC5004, a small-molecule GLP-1 receptor agonist licensed from Eccogene.
- Roche: Entered the space through its $2.7 billion acquisition of Carmot Therapeutics, which included oral metabolic assets.
- Structure Therapeutics: Recently reported positive Phase 2a data for its oral GLP-1, GSBR-1290, which showed "injectable-like" efficacy.
- Viking Therapeutics: Advancing VK2735, a dual GLP-1/GIP receptor agonist that has shown promising results in oral tablet form.
Corxel’s strategy relies on the premise that "treatment persistency" is just as important as "peak efficacy." By positioning CX11 as a drug with a superior GI safety profile, Corxel aims to capture the segment of the patient population that cannot tolerate the side effects of more potent or peptide-based medications.
Regulatory Outlook and Future Implications
The FDA has provided Corxel with guidance on the regulatory path forward, a critical hurdle for any clinical-stage biotech. The agreed-upon design for the Phase 3 trial ensures that the company’s data collection will meet the standards required for a New Drug Application (NDA) filing.
Furthermore, Corxel’s development of CX12—a small-molecule amylin receptor agonist—suggests a broader strategy of combination therapy. Amylin is a hormone that works alongside insulin and GLP-1 to regulate appetite and blood glucose. Many researchers believe that combining GLP-1 agonists with amylin agonists could lead to even greater weight loss with fewer side effects than current monotherapies.
The transition to a public company via a SPAC merger allows Corxel to bypass the traditional IPO route, which can be more time-consuming in volatile market conditions. For Amanat Acquisition Corp., the deal represents the fulfillment of its mandate to identify a high-growth target in the healthcare sector.
As the transaction moves toward a 2027 close, the industry will be watching Corxel’s type 2 diabetes data and the initiation of its Phase 3 obesity trials. If CX11 can maintain its tolerability advantage while delivering double-digit weight loss in a larger patient population, Corxel could emerge as a primary challenger to the pharmaceutical giants currently dominating the metabolic health landscape. The company’s current management team is expected to remain in place, though a search for a permanent U.S.-based CEO is ongoing to lead the firm through its next chapter of commercialization and growth.
